Abstract
Preventing the development and progression of diabetic kidney disease is one of the key factors influencing the prognosis of patients with type 2 diabetes mellitus. Incretin therapy, and in particular gliflozin therapy, represents a major breakthrough in influencing the mechanisms involved in the pathogenesis and progression of diabetic kidney disease.
The results of recent studies point out the importance of non-glycemic effects in influencing cardiovascular risk and the concomitant slowing of the progression of decreased renal function also in patients without a history of diabetes mellitus.